|Bid||240.80 x 800|
|Ask||246.43 x 800|
|Day's Range||242.63 - 245.95|
|52 Week Range||129.21 - 248.40|
|Beta (5Y Monthly)||0.26|
|PE Ratio (TTM)||36.45|
|Earnings Date||Aug 03, 2021|
|Forward Dividend & Yield||3.40 (1.39%)|
|Ex-Dividend Date||Aug 12, 2021|
|1y Target Est||236.68|
Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla Repatha and other and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.
Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.